Adaptimmune Therapeutics plc (473A) — Free Cash Flow Generation Index

Latest as of June 2024: 0.98x

Adaptimmune Therapeutics plc (473A) has a Free Cash Flow Generation Index of 0.98x as of June 2024. Free cash flow of €46.65 Million represents 1% of operating cash flow (€47.40 Million). See working capital position of Adaptimmune Therapeutics plc to evaluate short-term liquidity relative to the company's equity base.

FCF Generation Index

0.98x

Free Cash Flow / Operating CF

Free Cash Flow

€46.65 Million

EUR

Operating Cash Flow

€47.40 Million

EUR

Capital Expenditures

€754.00K

EUR

Adaptimmune Therapeutics plc Free Cash Flow Generation Index (2021–2021)

Historical FCF Generation Index trend for Adaptimmune Therapeutics plc across 1 annual periods. Explore cash flow to debt ratio of Adaptimmune Therapeutics plc to assess how comfortably operating cash covers total debt obligations.

Annual Free Cash Flow Generation for Adaptimmune Therapeutics plc (2021–2021)

Year-by-year Free Cash Flow Generation Index for Adaptimmune Therapeutics plc. For the full company profile including market capitalisation, see 473A stock market capitalisation.

Year	FCG Index	Free Cash Flow (EUR)	Operating CF	Capital Expenditures	YoY Change
2021	0.18x	€1.95 Million	€10.73 Million	€8.57 Million	—

FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).